SCI 발표논문

SCI 발표논문

← SCI 발표논문 목록

Oncologist. 2022;27(12):e931-e937.

Evaluation of Seropositivity After Standard Doses of Vaccination Against SARS-CoV-2 in Patients With Early Breast Cancer Receiving Adjuvant Treatment.

, , , , , , , , , ,

제1저자 김진영, 장의진 · 교신저자 박완범, 이경훈

PMID 36218350 PMC9732225 DOI 10.1093/oncolo/oyac196 IF 4.7 감염내과
소속 (2)
  1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.
  2. Cancer Research Institute, Seoul National University, Seoul, Korea.

Abstract

BACKGROUND Coronavirus disease 2019 (COVID-19) pandemic affected millions of individuals, and patients with cancer are known to be more susceptible. Vaccines against SARS-CoV-2 have been developed and used for patients with cancer, but scarce data are available on their efficacy in patients under active anti-cancer therapies.

MATERIALS AND METHODS In this study, we semi-quantitatively measured the titers of the immunoglobulin G against the anti-spike protein subunit 1 of SARS-CoV-2 after vaccination of patients with early breast cancer undergoing concurrent chemotherapy, endocrinal or targeted non-cytotoxic treatments, and no treatments.

RESULTS Standard doses of COVID-19 vaccines provided sufficient immune responses in patients with early breast cancer, regardless of the type of anticancer therapies. However, the post-vaccination serum anti-spike antibody titers were significantly lower in the patients under cytotoxic chemotherapy.

CONCLUSION Our study emphasizes the importance of the personalized risk stratification and consideration for booster doses in more vulnerable populations.

© The Author(s) 2022. Published by Oxford University Press.

Keywords

COVID-19SARS-CoV-2 vaccinesadjuvant chemotherapyanti-spike antibodybreast cancer

Figures

Figure 1.
Figure 1. Patient enrollment: flowchart showing the patient enrollment and selection.
Figure 2.
Figure 2. Proportion of seroconversion in patients: seroprevalence proportions in (A) all early breast cancer patients, (B) with cytotoxic chemotherapy treatments, (C) with non-cytotoxic treatments, and (D) without anti-cancer treatment.
Figure 3.
Figure 3. Antibody titers with anti-cancer treatments: SARS-CoV-2 anti-S IgG antibody titers after each dose of vaccinations in early breast cancer patients with cytotoxic chemotherapy treatment, with non-cytotoxic treatment, and without anti-cancer treatment.
Figure 4.
Figure 4. Antibody titers with steroid treatments in chemotherapy group: Comparison of SARS-CoV-2 anti-S IgG antibody titers after each dose of vaccinations with and without corticosteroid treatments in cytotoxic chemotherapy group.

그림 출처: PubMed Central 공개 논문 (PMC9732225)

그 밖의 정보
출판 형태
Journal Article, Research Support, Non-U.S. Gov't
저널
The oncologist · eISSN 1549-490X
MeSH
Humans · Female · SARS-CoV-2 · COVID-19 Vaccines / therapeutic use · Breast Neoplasms* / drug therapy · COVID-19* / prevention & control · Patients
Substances
COVID-19 Vaccines
참고문헌
27편